BioSig Brings on Former AtriCure Executive as New CEO

BioSig Technologies Inc., a medical device company that makes technology solutions for the electrophysiology market, announced today the appointment of David J. Drachman as president, CEO and chairman of the board, effective immediately. Drachman transitions leadership from co-founder and board member Kenneth L. Londoner.

Drachman brings 27 years of leadership in the cardiovascular medical device industry to BioSig. Most recently, he served as president, CEO and director of AtriCure Inc., a leader in the surgical treatment of atrial fibrillation (AF). During his tenure, the AtriCure team expanded their product portfolio from one to six unique platforms and had grown from a startup to a market leader with distribution channels in more than 30 countries. Drachman also held key executive positions at Biosense Webster and led the company’s initial commercialization process. Electrophysiology company Biosense Webster is now owned by Johnson & Johnson. Additionally, David served as acting CEO, worldwide president and director of Impulse Dynamics, and had high-level positions at Ventritex and Boston Scientific.

“Dave is one of the preeminent leaders of our industry,” said Kenneth L. Londoner, co-founder and departing chairman and CEO of BioSig. “BioSig and its stakeholders will enormously benefit from his deep domain expertise and achievements. We are delighted to welcome Dave as a leader to the team and look forward to many years of growth and success.”

“It is a privilege to join the BioSig team,” said Drachman. “We share the same passion for innovation and execution. I’m confident that BioSig’s novel technologies will provide important solutions for electrophysiologists to ultimately improve patient outcomes, and deliver market-leading performance.”

BioSig Technologies focuses on clinical solutions for the diagnosis and treatment of arrhythmia. The company is based in Los Angeles, Calif.